News | April 04, 2022
USFDA grants priority review to Roche’s Actemra/RoActemra to treat Covid-19
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
The investment will accelerate the overall Sarclisa development program
Macitentan tablets, 10 mg have an estimated market size of US $ 797 million for twelve months ending Dec 2021 according to IQVIA
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
Bebtelovimab neutralizes Omicron as demonstrated by pseudo virus and authentic virus data
Subscribe To Our Newsletter & Stay Updated
